Paul Feldman Biography
Paul L. Feldman received his BS in 1983 from Duke University and Ph.D. in 1987 from the University of California, Berkeley working with Professor Henry Rapoport on alkaloid total synthesis and heterocyclic methodology. He joined Glaxo Pharmaceuticals, Research Triangle Park, North Carolina in 1987. During Paul’s tenure in the pharmaceutical industry his role has evolved into positions of increased leadership and responsibility. From 1987-1995 Paul worked on a variety of drug discovery programs in the anesthesia, anti-inflammatory, and anti-cancer areas. During this time he led the team of scientists that discovered the marketed ultra short-acting analgesic opioid agonist remifentanil (Ultiva). In addition, he and academic collaborators worked on the biochemistry of mammalian nitric oxide production. In 1995 he was promoted to department director with Glaxo Wellcome Pharmaceuticals. From 1995-2000 Paul’s department worked on the discovery of antiviral agents for treatment of HIV and HSV. One of the highlights during this period was the discovery of the marketed HIV protease inhibitor, fosamprenavir (Lexiva/Telzir). In 2000 Paul became Vice President of Chemistry for the Metabolic and Viral Diseases for GlaxoSmithKline Pharmaceuticals. Several clinical candidates were discovered in this 8-year period and advanced through phase 2 clinical studies. One of the assets, the HIV integrase inhibitor dalutegravir (Tivicay), advanced to the market in 2013. In 2010 Paul was named Senior Vice President. Currently he leads the Enteroendocrine Discovery Performance Unit and is part of GSK’s leadership team of the Metabolic Pathways Cardiovascular Unit. In addition, Paul leads GSK R&D’s Center of Excellence for Medicinal Chemistry. Beyond his duties at GSK Paul has served as an adjunct Professor of Chemistry, Duke and North Carolina State Universities, chair of Heterocyclic Compounds Gordon Research Conference (2000), member at large (2000-2003) and alternate councilor (2012-2014) to the Executive Committee in the Division of Organic Chemistry of the American Chemical Society, and chair of the Division of Organic Chemistry Fellowship Evaluation Committee (2003). Paul has approximately 50 journal publications and 40 invited lectures.